Fig. 2From: Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patientsSurvival analyses by the Kaplan–Meier method according to whether or not had received cytoreduction surgery after PARPi resistant (n = 44). (A) Progression-free survival 2 (PFS2) and (B) PFS2 – PFS1Back to article page